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Starting from the observation that a number of consecutive patients with non-Hodgkin’s
lymphoma (NHL) resulted positive for hepatitis C virus (HCV) antibodies on routine test-
ing, we set up a survey for HCV contact prevalence in all patients with lymphoproliferative
disorders (LPD) followed in our institution. We searched for HCV antibodies by a third-
generation ELISA technique, followed by a confirmation test (RIBA III); serum viral RNA
and HCV genotype were investigated by a RT-PCR technique. We screened a total of 315
patients suffering from B-NHL (91), multiple myeloma (56), MGUS (48), chronic lympho-
cytic leukemia (57), Waldentro¨m’s macroglobulinemia (13), Hodgkin’s disease (HD)(43),
and T-NHL (9). While only 1 of 52 patients with a non-B-LPD (HD or T-NHL) had signs of
HCV contact (i.e., 1.9%, which is in the range of the normal population in the South of
Italy), 59 of 263 patients with a B-LPD (22.4%) had HCV antibodies or RNA, or both, with
no major differences among the various types of disorders, except for WM, in which the
rate was higher (61.5%). The same prevalence was found for patients tested at diagnosis
or during the follow-up, and in transfused or never-transfused patients. Only a few pa-
tients were aware of having a liver disease; one-half of HCV-positive patients never had
transaminase increase. A review of data from Central and Northern Italy is included,
showing similar findings; a report from Japan has confirmed such an association, while
limited surveys in England have not revealed any correlation. These findings may have
important biological and clinical implications. Am. J. Hematol. 55:77–82, 1997.
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INTRODUCTION
Tests for highly contagious viral infections are now
routine for patients who must undergo any surgical pro-
cedure. Such tests usually include hepatitis B virus
(HBV) and human immunodeficiency virus (HIV). For
reasons that are still unclear, hepatitis C virus (HCV)
demonstrates uneven spreading, with some countries
more affected than others. In Italy, HCV contact in the
general population is estimated at 1–3% [1], with minor
variations between the North and the South (1.28% vs.
1.51%) [2] and larger variations among different groups
of subjects (e.g., 0.35% in blood donors, 80% in drug
abusers) [3]. In a set of consecutive patients with sus-
pected lymphoma undergoing lymph node biopsy at our
hospital we found an unexpectedly high prevalence of
HCV-positive status. Similar findings have been recently
reported also from central [4,5] and northern [6,7] Italy.
In order to quantitate this finding and to find out whether
the same applies to lymphoproliferative disorders (LPD)
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other than lymphomas, we have screened for HCV all our
patients suffering from an LPD and have explored cor-
relations with a number of clinical findings. The results
of this survey confirm that HCV contact has occurred
much more frequently in patients with an LPD of B-cell
lineage, as compared to the normal population and to
patients with a non-B-LPD.
PATIENTS AND METHODS
Patients
All patients attending our institution from November
1994 to November 1995 for an LPD (new patients, those
in treatment and those in post-treatment follow-up) were
grouped into two categories: B-LPD and non-B-LPD.
Patients suffering from multiple myeloma (MM), mono-
clonal gammopathy of uncertain significance (MGUS),
chronic lymphocytic leukemia (CLL), Waldenstro¨m’s
macroglobulinemia (WM), and hairy cell leukemia
(HCL) were directly included in the B-LPD group, pa-
tients with Hodgkin’s disease (HD) in the non-B group.
Patients with non-Hodgkin’s lymphoma (NHL) were ap-
propriately grouped only if immunological markers had
proven a B- or T-cell origin. We used standard diagnostic
criteria for disease classification; however, in the MGUS
group, only patients with a substantial monoclonal com-
ponent (MC), i.e., IgG > 1,000 mg/dl and IgA > 600
mg/dl, were considered. As for patients with an IgM MC,
they were operatively classified as MGUS if the MC was
800–2000 mg/dl, and as WM if > 2,000 mg/dl. NHL
were graded according to the Working Formulation [8].
The vast majority of patients were diagnosed, treated,
and followed up on outpatient basis.
Control Groups
The prevalence of HCV exposure in blood donors at-
tending our institution was obtained from the Blood
Bank. In order to have a more appropriate control group,
we screened 93 subjects > 40 years of age suffering from
a metabolic disorder (diabetes, dyslipemia, vasculopa-
thy), attending our hospital on an outpatient basis.
Cryoglobulins
The presence of cryoglobulins was tested qualitatively
on serum obtained from blood clotted at 37°C, cooled at
4°C for 4 days. Samples containing any amount of pre-
cipitate that could be dissolved at 37°C were considered
positive.
HCV Testing
Serum samples from all patients and control group
were screened for HCV exposure by testing (1) anti-
HCV-Ab by a third-generation enzyme-linked immuno-
sorbent assay (ELISA) technique (EIA Seroplate, Ares-
Serono or Inno-Lia III, Innogenetics, Zwijnaarde, Bel-
gium), followed, in case of positivity, by a confirmation
test with a third-generation RIBA (Chiron RIBA 3.0,
Chiron Corp., Emeryville, USA); and (2) serum HCV-
RNA by a polymerase chain reaction (PCR)-based tech-
nique (PCR Amplicor, Roche, Branchburg, USA). Most
sera that were positive for viral RNA were also charac-
terized for HCV genotype using a PCR-based technique
(Inno-Lipa, Innogenetics). HBV markers were tested by
ELISA (Radim EIA, Radim Spa, Pomezia, Italy). HCV
status was defined as positive (HCV positive) when ei-
ther anti-HCV antibodies or HCV-RNA, or both, had
been found in the serum. No patient with overt high risk
of viral infections (drug abusers, HIV-positive patients)
was considered in this study. Also, LPDs developing in
patients with overt cirrhosis or mixed cryoglobulinemia
were excluded. HIV antibodies were checked only for
patients admitting to be at risk.
Informed consent was obtained in all cases. Sixty pa-
tients were tested at diagnosis, 255 during or after treat-
ment. Chi-square, Fisher’s exact test, and Student’s t-test
were used for statistical analysis comparison, when ap-
propriate.
RESULTS
A total of 263 patients with a B-LPD and 52 with a
non-B-LPD were screened. HCV positivity was docu-
TABLE I. Prevalence of HCV Contact in Our Series of Patients
With an LPD and in Control Groups
Tested Positivea %
B-LPD
B-NHL 91 21 23.1
MM 56 9 16.1
MGUSb 48 11 22.9
CLL 48 8 16.7
WMc 13 8 61.5
HCL 7 2 28.6
Total 263 59 22.4
Non-B-LPD
HD 43 1 2.3
T-NHL 9 0 0
Total 52 1 1.9
Control groups
Blood donors, any age 1,568 30 1.9
Blood donors, >40 yr 500 12 2.4
Patients with a metabolic
disorder, >40 yr 93 5 5.4
aHCV/Ab positive and/or HCV/RNA positive.
bWith a substantial monoclonal component (MC).
cIgM MC >2000.
HCV, hepatitis C virus; LPD, lymphoproliferative disease; NHL, non-
Hodgkin’s lymphoma; MM, multiple myeloma; MGUS, monoclonal gam-
mopathy of uncertain significance; CLL, chronic lymphocytic leukemia;
WM, Waldenstro¨m’s microglobulinemia; HCL, hairy cell leukemia; HD,
Hodgkin’s disease.
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mented in 22.4% of patients with a B-LPD and in 1.9%
of patients with HD or T-NHL (Table I). The difference
was highly significant (P 4 0.0016). The male-to-female
ratio was 1.2. Most positive patients (42 of 60) had both
anti-HCV Ab and viral RNA in the serum; 15 patients
had only Ab and 3 only RNA. A few patients were ex-
cluded from the study: two because of a previous history
of cirrhosis, two because of a previous history of mixed
cryoglobulinemia, one drug abuser, and two HIV posi-
tive.
In the control group, composed of diabetic, dyslipe-
mic, or vasculopathic patients older than 40 years of age,
HCV positivity was documented in 5.4% of the subjects,
a prevalence that was statistically different when com-
pared to B-LPD patients (P 4 0.0004) and nonsignifi-
cant when compared to non-B-LPD (P 4 0.3). In the
cohort of blood donors, HCV-positive prevalence was
1.9% in the whole group and 2.4% for subjects >40 years
of age; the difference was highly significant versus B-
LPD patients (P < 0.000001) and nonsignificant versus
non-B-LPD patients (P 4 0.6).
In the set of B-LPD patients, we further analyzed pos-
sible correlations between HCV status and a number of
clinical findings:
1. Transfusions: Of the patients who had received at
least one transfusion before being tested (n 4 45), 26.7%
were HCV positive; in patients who had never been
transfused (n 4 218), the figure was 21.6% (P 4 0.60).
Thus, even patients who had never been transfused
showed a high prevalence of HCV contact.
2. Time of testing: Forty-five patients were tested at
diagnosis and 22.2% were found to be HCV positive; 218
were tested during follow-up and 22.5% were HCV posi-
tive. Thus, disease duration and type of treatment bore no
relationship to HCV status.
3. Hepatitis B exposure: In 139 patients who were
negative for HBV markers, the percentage of HCV posi-
tive was 25.2%; in 85 patients with evidence of HBV
contact the percentage of HCV positive was 24.7%.
Thus, no relation was found between HCV and HBV
exposure, stressing the absence of a higher risk of viral
infection in our HCV-positive patients. The high rate of
HBV positivity in our B-LPD series (37.9%) did not
differ significantly, as compared to that in the non-B
group (23.9%; P 4 0.1). These values are in the range
reported previously in population screenings for adult or
elderly subjects in Italy [9,10].
4. Age: Since the probability of HCV contact in en-
demic areas increases with the time of exposure, we
tested for a possible correlation between age and HCV
status. The mean age was 60.3 (median 62, range 15–88)
for HCV-negative patients and 61.4 (median 61, range
41–88) for HCV-positive patients (P 4 0.57). As ex-
pected, mean and median age in the group of non-B-LPD
were significantly lower (35.5 and 31, respectively, range
14–77), due to the different age incidence of HD and
T-NHL. In order to avoid any bias due to age difference,
in the control group of patients with metabolic disorders
we included only patients >40 years old, with an age
distribution (mean 54.4, median 54, range 40–77) com-
parable to that of B-LPD patients.
5. Transaminase elevation: An increase of serum
transaminase value (AST and/or ALT >n.v. × 2) was
noticed at diagnosis or any time during follow-up in
13.4% of HCV-negative and in 50% of HCV-positive
patients (P 4 0.000001). While such a correlation was
largely expected, it is noteworthy that one-half of HCV-
positive patients in our series never showed increased
transaminases, even on repeated testing. Liver biopsies
were not performed. In HCV-positive patients, increased
transaminases were found in 4 of 10 patients studied at
diagnosis and in 25 of 49 studied during follow-up; thus,
it is unlikely that enzyme elevation bore any relationship
to chemotherapy-induced viral reactivation.
6. NHL grading: When NHL patients were grouped
according to the Working Formulation classification, the
rate of HCV positivity was 25% in low grade, 25.8% in
intermediate and 18.8% in high grade. The trend in favor
of low and intermediate grade did not reach statistical
significance (P 4 0.77), possibly because of the small
number of patients in each subgroup.
7. Type of immunoproliferative disorder: The overall
rate of HCV-positive status in all patients with a mono-
clonal component (MC) (i.e., MGUS, MM, and WM)
was 52.4% in those with IgM, 24.6% in those with IgG,
and 9.5% in those with IgA; a single HCV-positive pa-
tient was found among 18 patients with rarer immuno-
proliferative diseases (light chain disease, nonsecreting
MM, solitary plasmacytoma). With one exception, all
HCV-positive MM patients were in stage I.
8. Cryoglobulins: Patients known to have type II-
mixed cryoglobulinemia who had progressed to NHL
were excluded from this study. In our series, no patient
had clinical signs of cryoglobulinemia. On testing, no
patient had a relevant amount of serum cryoglobulins;
traces or small amounts were detected in 17 of 59 HCV-
positive patients (29%) (mostly in the NHL and the WM
groups), and in 4 of 72 HCV-negative patients (5%).
Among the patients with HD or T-NHL, 30 were tested,
and none had cryoglobulins.
9. HCV genotype: A screening of the viral genotype
was performed in 31 of 44 RNA-positive patients. We
found genotype 1a in six cases, 1b in nine cases, and 2a
in nine cases; genotype was unclassifiable in the remain-
ing seven. Altered transaminases were found in all pa-
tients with genotype 1a, in 8 of 9 with genotype 1b, and
in 3 of 9 with genotype 2a. No clear correlation emerged
between genotype and type of LPD (Table II).
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DISCUSSION
Epidemiology
We report an exceedingly high prevalence of HCV
contact in all groups of patients with a B-LPD, as com-
pared to that in the normal population of the same geo-
graphic area and to that in control groups consisting of
patients with non-B-LPDs, patients with a metabolic dis-
ease, and blood donors. Using third-generation reagents
for HCV testing, there was no discrepancy between
ELISA and RIBA, and viral RNA was detected in most
patients, thus ruling out false-positive results. Statistical
analysis ruled out the possibility that the high prevalence
could be attributed to previous transfusions, duration of
hematological disease, or patient age. As for the latter, a
bias was present in the control group of non-B-LPD
(younger patients), but it could not explain the huge dif-
ference of prevalence; no bias was present in the control
group of patients with a metabolic disease, since this
group was age matched. Patients with a LPD evolving
from liver cirrhosis or mixed cryoglobulinemia were ex-
cluded. No bias for a population having a high risk of
viral infection was present in our series (drug abusers and
HIV-positive patients had been excluded). An internal
control was that HCV-positive patients did not show a
higher prevalence of HBV contact. Only a few patients
were aware of having liver disease; on testing, one-half
of HCV-positive patients never exhibited abnormal
transaminases. HCV infection without any sign of liver
damage has been also reported in one-third of patients
with mixed cryoglobulinemia [11].
The prevalence of HCV exposure in patients with a
LPD was recently surveyed in other parts of Italy
[4–7,12–20], in Japan [21], and in England [22–24], with
variable results. As for Italy, the percentages are rather
similar in southern, central, and northern Italy, with mi-
nor differences among the various disease subgroups,
probably related to the small number of patients tested
(Table III). In several series, the highest rate of HCV
positivity is found in patients with a monoclonal IgM
component (MGUS, WM). In our study as in others, the
set of patients with HD or T-NHL, showing the same
HCV-positive prevalence as that of the general popula-
tion in Italy, constitutes a strong internal control, proving
that our methodology was appropriate and that the results
are specific. A HCV-positive prevalence of 17.9% in
patients with monoclonal gammopathies compared to
10% of an age-matched control group was found not
statistically significant in a recent report from another
region from southern Italy [17], probably due to the small
sample size. Results similar to ours have been recently
published in Japan [21]: exposure to HCV was detected
in 22% of patients with B-cell NHL and never in non-
B-cell NHL and in HD. At variance, British investigators
did not find increased prevalence of HCV exposure in
patients with NHL in the United Kingdom [22–24].
Studying HCV genotype in our HCV–mRNA-positive
patients, we did not find the prevalence of type 1b re-
ported in Italian patients with non-post-transfusional
chronic liver disease [25]. No evidence of correlation
between specific genotype and type of LPD has emerged
from our study, as well as from others [13]. Patients with
type 2a had more often a normal transaminase level: a
milder hepatic involvement by type 2a has been already
noticed [26].
TABLE II. HCV Genotype in the Various Lymphoproliferative
Disorders
Disease type
Genotype
1a 1b 2a 2b Unclassifiable
NHL 3 2 4 0 1
MM 1 2 4 0 2
MGUS 1 3 0 0 2
CLL 0 2 1 0 1
WM 1 0 0 0 1
See Table I for abbreviations.
TABLE III. Studies on the Prevalence of Exposure to HCV in
Patients With LPD in Italy
Disease type n %HCV+ Ref.
NHL 50 34 4
199 28 6
311 9 7
150 25 12
69 42 13
24 21 14
150 27 18
126 20 19
47 15 20
91 23 p.r.
Total: 1,217 22
CLL, HCL 40 5 12
50 18 18
29 21 20
55 18 p.r.
Total: 174 15
MM, MGUS 78 4 7
90 16 12
91 14 13
89 14 17
49 24 20
104 19 p.r.
Total: 501 15
WM 12 8 13
6 100 15
14 20 16
13 23 17
12 17 20
13 61 p.r.
Total: 70 36
p.r., present report; see Table I for all other abbreviations.
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We think it would be desirable to carry out surveys on
HCV prevalence in patients with LPDs in other coun-
tries, especially in those in which HCV infection is en-
demic, in order to find out whether the association we
report here is a problem of a few countries or a more
general phenomenon.
Role of HCV in B-Cell NHL
The strong association between exposure to HCV and
B-LPDs can be explained in either of two ways: (1)
patients with a B-LPD have increased risk of HCV in-
fection, and (2) HCV-infected patients have increased
risk of developing a B-LPD. Several of our findings ar-
gue against the former hypothesis: the signs of exposure
to HCV have been found with the same prevalence at
diagnosis and during follow-up; most LPD patients were
never transfused. The latter hypothesis remains specula-
tive, although intriguing. HCV is not only hepatotropic,
but also sialotropic [27] and lymphotropic; it may be
detected in hepatic lymphocytes [28], in peripheral blood
mononuclear cells of infected patients [11,13,29,30] and
in lymphoma tissues [31]. HCV is strongly associated
with essential mixed cryoglobulinemia [32], which can
be regarded as a smoldering low-grade lymphoma with a
clonal B-cell expansion and a monoclonal IgM compo-
nent. Even in patients with HCV-positive chronic hepa-
titis without cryoglobulinemia a subclinical clonal B-cell
expansion has been demonstrated by molecular analysis
[33]. The presence of traces of cryoglobulins in one-third
of our HCV-positive patients is also intriguing; as these
patients have overt LPD and no clinical signs of cryo-
globulinemia, it is unlikely that all of them had had sub-
clinical cryoglobulinemia subsequently progressing to
LPD. We think that the biological relevance of the pres-
ence of cryoglobulins should not be overestimated: it is
not a marker of a different disease, rather, it could be
simply another sign of exposure to HCV.
If HCV is indeed causative of lymphoid malignancies,
it could do so either by acting directly (i.e., producing an
early hit in a sequence of oncogenic events), or indirectly
(i.e., by causing expansion of lymphoid clones that may
subsequently undergo mutational events). In addition, in-
teractions with other undiscovered or unknown viruses
(‘‘passenger viruses’’) cannot be ruled out. Other ex-
amples of HCV involvement in oncogenesis do exist:
hepatic carcinoma often develops in patients with HCV-
positive chronic hepatitis [34]. HCV has been also in-
criminated as a trigger of autoimmunity [20,35], and au-
toimmune disorders may predispose to NHL. Finally,
there are a few examples of lymphoproliferative disor-
ders not only caused but also maintained by infectious
agents: Epstein-Barr virus (EBV)-induced lymphomas in
transplanted patients [36] and Helicobacter pylori-
related gastric MALT lymphomas [37]. Two very recent
reports from other parts of Italy [19,38] have stressed the
high prevalence of HCV-positive in patients with MALT
lymphoma (36.4% and 50%, respectively). It would be
interesting to verify whether some kind of antiviral
therapy is of any benefit for the subset of HCV-positive
LPD patients. We have preliminary unpublished results
of a higher response rate to interferon-a (IFN-a) in the
subgroup of HCV-positive Waldenstro¨m’s macroglobu-
linemia patients.
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NOTE ADDED IN PROOFS.
A high juvalence of HCV positivity has been recently
reported also for patient suffering from B-NHL in USA
(Zuckerman et al, Blood 88 (suppl. 1), 1996, Abst 877.
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